Published in Schizophr Bull on November 20, 2015
Treating Negative Symptoms in Schizophrenia: an Update. Curr Treat Options Psychiatry (2016) 0.75
Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia? Front Neurosci (2017) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl (1970) 10.05
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl (1989) 4.53
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl (1987) 4.49
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ (2003) 4.24
Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev (1998) 2.50
Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl (2000) 2.39
Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry (2008) 1.78
Modulation of brain dopamine transmission by sex steroids. Rev Neurosci (1994) 1.52
The role of estrogens in schizophrenia gender differences. Schizophr Bull (1990) 1.41
Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment (2012) 1.37
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J (1996) 1.14
Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res (2007) 1.12
Influence of gender on social outcome in schizophrenia. Acta Psychiatr Scand (2002) 1.06
Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol (2014) 1.06
Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry (2000) 1.04
Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones. Endocrinology (2009) 1.04
Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry (2014) 1.03
Estrogen for schizophrenia. Cochrane Database Syst Rev (2005) 1.03
Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology (2010) 1.02
Estradiol levels in psychotic disorders. Psychoneuroendocrinology (2001) 1.00
Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.95
Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology (2009) 0.95
Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry (2015) 0.92
Selective Estrogen Receptor Modulation Increases Hippocampal Activity during Probabilistic Association Learning in Schizophrenia. Neuropsychopharmacology (2015) 0.92
Effects of selective estrogen receptor modulators on allocentric working memory performance and on dendritic spines in medial prefrontal cortex pyramidal neurons of ovariectomized rats. Horm Behav (2012) 0.91
Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv (2013) 0.91
Estrogens and gonadal function in schizophrenia and related psychoses. Curr Top Behav Neurosci (2011) 0.88
Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry (2011) 0.88
Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology (2002) 0.87
Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev (2002) 0.87
Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a dutch catchment area. Am J Geriatr Psychiatry (2012) 0.86
Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am J Geriatr Psychiatry (2003) 0.78
Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab (2012) 0.78
Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiol Aging (2014) 0.78
Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru (2014) 0.77
Review of raloxifene and its clinical applications in osteoporosis. Expert Opin Pharmacother (2002) 0.77
Elevated fasting plasma cortisol is associated with ischemic heart disease and its risk factors in people with type 2 diabetes: the Edinburgh type 2 diabetes study. J Clin Endocrinol Metab (2010) 1.11
Higher requirements of dialysis in severe lithium intoxication. Hemodial Int (2012) 0.96
Transmitting biological effects of stress in utero: implications for mother and offspring. Psychoneuroendocrinology (2013) 0.96
Clinical implications of insight assessment in obsessive-compulsive disorder. Compr Psychiatry (2007) 0.94
Extensive genotyping of the BDNF and NTRK2 genes define protective haplotypes against obsessive-compulsive disorder. Biol Psychiatry (2007) 0.90
Personality dimensions in obsessive-compulsive disorder: relation to clinical variables. Psychiatry Res (2007) 0.89
Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care (2010) 0.88
REPYFLEC cognitive remediation group training in schizophrenia: Looking for an integrative approach. Schizophr Res (2012) 0.88
Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol (2013) 0.88
Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry (2011) 0.88
Stressful life events at onset of obsessive-compulsive disorder are associated with a distinct clinical pattern. Depress Anxiety (2011) 0.87
Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder. J Psychiatry Neurosci (2012) 0.85
Brain structural imaging correlates of olfactory dysfunction in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
Abnormal functioning of the semantic network in schizophrenia patients with thought disorganization. An exemplar production task. Psychiatry Res (2012) 0.81
Unhealthy lifestyle in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology (2013) 0.81
Verbal and nonverbal memory processing in patients with obsessive-compulsive disorder: its relationship to clinical variables. Neuropsychology (2008) 0.80
Obsessive-compulsive and eating disorders: comparison of clinical and personality features. Psychiatry Clin Neurosci (2007) 0.79
Cognitive profiles of three clusters of patients with a first-episode psychosis. Schizophr Res (2013) 0.78
Baseline Predictors for Success Following Strategy-Based Cognitive Remediation Group Training in Schizophrenia. J Nerv Ment Dis (2016) 0.78
The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis. Psychiatry Res (2013) 0.77
Individual versus group cognitive-behavioral treatment for obsessive-compulsive disorder: a controlled pilot study. Psychother Res (2008) 0.77
Olfactory identification and discrimination in obsessive-compulsive disorder. Depress Anxiety (2011) 0.77
A case-control study of sex differences in strategic processing and episodic memory in obsessive-compulsive disorder. Compr Psychiatry (2009) 0.77
Individual versus group cognitive behavioral treatment for obsessive-compulsive disorder: follow up. Psychiatry Clin Neurosci (2008) 0.76
Onset of unipolar depression or bipolar disorder prior or close to menarche. J Clin Psychiatry (2006) 0.75
Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study. Eur J Endocrinol (2012) 0.75
Reproductive hormone sensitivity and obsessive-compulsive disorder: are there differences in the genetic predisposition between symptom dimensions? J Clin Psychiatry (2011) 0.75
Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol (2016) 0.75
Psychosis and gender. Schizophr Res Treatment (2012) 0.75
Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. Int Clin Psychopharmacol (2017) 0.75
Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Eur Arch Psychiatry Clin Neurosci (2019) 0.75
Oral contraceptive pill use and changes in obsessive-compulsive symptoms. J Psychosom Res (2006) 0.75